Concurrent administration of sunitinib (VEGFR and PDGFR receptor tyrosine kinases inhibitor (RTKI)) and HGF/c-MET inhibitors effectively inhibited angiogenesis and tumor growth (Lu et al., 2012). The gene discussed is KDR; the disease is neoplasm.